Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Induction Therapy
Latest Information Update: 13 Sep 2023
At a glance
- Drugs Annamycin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Moleculin Biotech
- 13 Jul 2023 According to a Moleculin Biotech media release, results from this trial were published in the peer-reviewed British Journal of Cancer Research.
- 13 Jul 2023 Results presented in the Moleculin Biotech Media Release.
- 13 Feb 2023 According to a Moleculin Biotech media release, The clinical study report for MB-105 has been finalized, internally published and reviewed and the Company expects to share detailed data in a paper and/or publication in the near future.